Copyright
©The Author(s) 2020.
World J Clin Cases. May 26, 2020; 8(10): 1878-1886
Published online May 26, 2020. doi: 10.12998/wjcc.v8.i10.1878
Published online May 26, 2020. doi: 10.12998/wjcc.v8.i10.1878
Table 1 Comparison of general information between the two groups
Ligliptin treatment group (n = 54) | Gliquidone treatment group (n = 56) | P value | |
Gender: Male/female | 30/24 | 33/23 | 0.721 |
Age (yr) | 50.38 (7.82) | 49.72 (9.10) | 0.685 |
Duration of diabetes (yr) | 7.80 (1.12) | 8.04 (1.40) | 0.324 |
BMI (kg/m2) | 23.40 (3.11) | 22.74 (2.87) | 0.250 |
Table 2 Comparison of blood glucose levels before and after treatment between the two groups
Ligliptin treatment group | Gliquidone treatment group | P value | |
Number of cases | 54 | 56 | |
FBG (mmol/L) | |||
Before treatment | 8.90 (1.28) | 8.78 (1.30) | 0.627 |
After treatment | 7.13 (1.05)a | 7.15 (1.01)a | 0.919 |
2hPG (mmol/L) | |||
Before treatment | 12.05 (1.43) | 12.10 (1.51) | 0.859 |
After treatment | 8.15 (1.65)a | 8.20 (1.70)a | 0.876 |
HbA1c (%) | |||
Before treatment | 7.99 (1.40) | 7.94 (1.31) | 0.847 |
After treatment | 7.00 (1.22)a | 6.93 (1.18)a | 0.760 |
Table 3 Comparison of renal function indexes between the two groups before and after treatment
Ligliptin treatment group | Gliquidone treatment group | P value | |
Number of cases | 54 | 56 | |
UAER (μg/min) | |||
Before treatment | 110.21 (18.82) | 107.82 (20.11) | 0.522 |
After treatment | 70.32 (11.21)a | 88.42 (12.27)a | 0.000 |
BUN (mmol/L) | |||
Before treatment | 6.10 (1.12) | 6.05 (1.09) | 0.813 |
After treatment | 5.77 (1.04)a | 5.79 (1.21)a | 0.926 |
Cr (μmol/L) | |||
Before treatment | 110.38 (15.56) | 108.82 (18.81) | 0.637 |
After treatment | 108.02 (12.38) | 107.22 (11.87) | 0.730 |
CysC (mg/L) | |||
Before treatment | 1.74 (0.30) | 1.78 (0.33) | 0.508 |
After treatment | 1.65 (0.33)a | 1.67 (0.35)a | 0.759 |
Table 4 Comparison of serum endogenous hydrogen sulfide and endothelial cell particles before and after treatment between the two groups
Ligliptin treatment group | Gliquidone treatment group | P value | |
Number of cases | 54 | 56 | |
H2S (μmol/L) | |||
Before treatment | 73.39 (9.28) | 75.58 (10.16) | 0.241 |
After treatment | 40.04 (8.82)a | 56.12 (9.90)a | 0.000 |
Endothelial cell granules | |||
Before treatment | 1459.28 (210.22) | 1430.04 (201.78) | 0.458 |
After treatment | 133.40 (34.39)a | 202.32 (50.43)a | 0.000 |
Table 5 Comparison of vascular endothelial function between the two groups before and after treatment
Ligliptin treatment group | Gliquidone treatment group | P value | |
Number of cases | 54 | 56 | |
FMD (%) | |||
Before treatment | 6.33 (1.21) | 6.40 (1.16) | 0.757 |
After treatment | 7.98 (1.22)a | 7.10 (1.13)a | 0.000 |
PAI-1 (ng/mL) | |||
Before treatment | 2.45 (0.43) | 2.51 (0.40) | 0.450 |
After treatment | 2.03 (0.56)a | 2.06 (0.61)a | 0.789 |
NO (μmol/L) | |||
Before treatment | 154.42 (32.19) | 150.03 (30.03) | 0.461 |
After treatment | 190.78 (30.32)a | 168.20 (29.37)a | 0.000 |
- Citation: Zhang J, Du YL, Zhang H, Sui H, Hou WK. Ligliptin for treatment of type 2 diabetes mellitus with early renal injury: Efficacy and impact on endogenous hydrogen sulfide and endothelial function. World J Clin Cases 2020; 8(10): 1878-1886
- URL: https://www.wjgnet.com/2307-8960/full/v8/i10/1878.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i10.1878